Company news
Inventiva Sa (EURONEXT:IVA) news
Every Inventiva Sa press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Inventiva to Present Multiple Abstracts at Paris MASH 2026
September 8, 2026
Inventiva présentera plusieurs abstracts lors du Congrès Paris MASH 2026
September 7, 2026
Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
September 2, 2026
Inventiva annonce la dernière visite du dernier patient de l’étude clinique de Phase 3 NATiV3 évaluant le lanifibranor dans la MASH
September 1, 2026
Inventiva Appoints Chris Benecchi as Chief Operating Officer
August 31, 2026
Inventiva nomme Chris Benecchi au poste de Chief Operating Officer
August 30, 2026
Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹
July 30, 2026
Inventiva Announces Preliminary Financial Results for the First Half of 2026¹
July 29, 2026
Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants
July 9, 2026
Results of the Votes of the Combined Shareholders’ General Meeting of June 30, 2026
July 2, 2026
Claret Capital Partners participates in €130m financing for Inventiva
June 16, 2026
Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development
June 16, 2026
Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing
June 12, 2026
Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents
June 9, 2026
Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris
June 2, 2026
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
June 2, 2026
Inventiva Reports 2026 First Quarter Financial Information¹
May 26, 2026
Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor
April 22, 2026
Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F
April 8, 2026
Inventiva reports 2025 full year results and provides a business update
March 30, 2026
Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results
March 23, 2026
Inventiva to Participate in Four Upcoming March Investor Conferences
February 26, 2026
Inventiva reports preliminary 2025¹ fiscal year financial results
February 17, 2026
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 4, 2026
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
January 26, 2026
Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025
November 28, 2025
Information relating to the stabilization activities carried out in the context of its recent offering
November 24, 2025
Inventiva reports 2025 Third Quarter Financial Information¹
November 21, 2025
Inventiva announces full exercise of Underwriters’ Option, bringing proceeds of Offering to approximately $172.5M
November 17, 2025
Inventiva announces trading resumption of its ordinary shares on Euronext Paris
November 13, 2025
Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares
November 13, 2025
Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris
November 13, 2025
Inventiva announces launch of public offering
November 12, 2025
Combined General Meeting of November 27, 2025 - Availability of the preparatory documents
November 6, 2025
Inventiva Announces the Implementation of a New ATM Program
October 14, 2025
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025
October 7, 2025
Inventiva Appoints Andrew Obenshain as Chief Executive Officer
October 1, 2025
Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update
September 29, 2025
Inventiva to Host Analyst and Investor Event on October 8, 2025
September 24, 2025
Inventiva to Participate in Upcoming September Investor Conferences
September 4, 2025
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
August 11, 2025
Inventiva Reports Preliminary 2025 First-Half Financial Information¹
July 29, 2025
Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance
July 9, 2025
Inventiva receives $10 million milestone payment from CTTQ
July 7, 2025
Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease
July 2, 2025
Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors
June 10, 2025
Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference
May 27, 2025
Inventiva reports 2025 First Quarter Financial Information¹
May 23, 2025
Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025
May 23, 2025